Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana

In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, we propose an ambispective study to evaluate the real-world effectiveness, safety, and immunogenicity of the recommended vaccines, IXCHIQ® and VIMKUNYA®, as defined by the French National Authority for Health (HAS).

Inclusion Criteria: Retrospective study VIMKUNYA or IXCHIQ * Adult (Aged 18 or above) * Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) Prospective study * VIMKUNYA: Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) * IXCHIQ: Adult (Aged 18 -64) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) Eligibility Criteria common to both groups * Agreeing to participate in study * Beneficiary of French social security coverage * Signature of informed consent form Exclusion Criteria: * Pregnant or breastfeeding women entering the prospective study * Vaccine (IXCHIQ or VIMKUNYA) contraindication for patients undergoing medical treatment * Persons under guardianship, curatorship or safeguard of justice * Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration * Missing French Social security coverage